Year: 2023

The Supervisory Board of AS Ekspress Grupp has elected Mr. Argo Rannamets as a new member of the Management Board and the Chief Financial Officer until October 31, 2026. His versatile experience from both a large international group and a start-up operating in a digital world, provides an unique combination that allows to contribute to the development of Ekspress Grupp. Starting from November 1, 2023, the Management Board of Ekspress Grupp will be as follows: Mari-Liis Rüütsalu (Chairman of the Board), Karl Anton and Argo Rannamets. The CV of Argo Rannamets is enclosed to the stock exchange release. Mari-Liis RüütsaluChairman of the Management Board+372 512 2591 mariliis.ryytsalu@egrupp.ee AS Ekspress Grupp is the leading Baltic media group whose key activities include web media content production, and publishing of newspapers,...

On Friday, 20 October 2023 at 9 am (EET), Coop Pank held an investor webinar, where the Chief Financial Officer Paavo Truu introduced the bank’s unaudited financial results of Third Quarter of 2023. Webinar was held in Estonian language. Coop Pank would like to thank all participants. Webinar recording is available here: https://youtu.be/aLj8QP9aheA Coop Pank’s report for unaudited results of Q3 2023 and the presentation is available here: https://view.news.eu.nasdaq.com/view?id=b49bb136d73e42764b382c2528433dfbc&lang=en Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The number of clients using Coop Pank for their daily banking has reached 175,000. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking...

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s Phase 2 basket trial of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38) at the ESMO Congress being held in Madrid from October 20-24, 2023. Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, shared encouraging clinical and biomarker data from patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥ 50% and recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20. As of the data cut off for this poster presentation, 10 out of 18 evaluable NSCLC...

GUANGZHOU, China, Oct. 22, 2023 (GLOBE NEWSWIRE) — FANHUA Inc. (“FANHUA” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, is excited to announce a strategic partnership with Asia Insurance Co., Ltd. (“Asia Insurance”), a wholly-owned subsidiary of Asia Financial Holdings Ltd (HKSE: 0662). Together, the two companies are forming two joint ventures: a life insurance brokerage company and an insurance technology company. FANHUA will be the majority shareholder of both joint ventures, with a 60% ownership stake in each. Both of the newly established joint ventures will be headquartered in Hong Kong. Commenting on this strategic move, Ben Lin, Co-Chairman and Chief Strategy Officer of FANHUA said, “The intermediary segment in Asia represents a unique greenfield opportunity within the financial...

(In United States dollars, except where noted otherwise) TORONTO, Oct. 22, 2023 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or “the Company”) (TSX: FM) announced today that Law 406, which approves the refreshed mining concession contract (“Concession Contract”) for the Cobre Panamá mine, was published in the Official Gazette of Panamá on October 20, 2023. On October 20, 2023, the National Assembly in Panamá approved Bill 1100, being the proposal for approval of the Concession Contract for the Cobre Panamá mine, in the third debate of the plenary session with a vote of 47 in favour out of a total of 55 votes registered. On the same day, President Laurentino Cortizo sanctioned Bill 1100 into Law 406 and this was subsequently published in the Official Gazette. The enactment of Law 406 marks the final step in revising...

Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathways sBLA for Dupixent to treat children aged 1 to 11 years with EoE is under Priority Review in the U.S.; if approved, Dupixent would be the first and only FDA-approved treatment for these children with EoEParis and Tarrytown, N.Y. October 22, 2023. Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) for up to one year (52 weeks) in children...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathways sBLA for Dupixent to treat children aged 1 to 11 years with EoE is under Priority Review in the U.S.; if approved, Dupixent would be the first and only FDA-approved treatment for these children with EoE PARIS and TARRYTOWN, N.Y., Oct. 22, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) showed consistent efficacy and safety for up to one year (52 weeks) in children aged 1 to 11 years with...